Rasmus Steen Pedersen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rasmus Steen Pedersen has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Kim Brøsen
Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark Odense Denmark
11 shared publications - Per Damkier
Department of Clinical Research, Faculty of Health Sciences University of Southern Denmark Odense Denmark
5 shared publications Mette Marie Hougaard Christensen
University of Southern Denmark
3 shared publicationsF. Nielsen
University of Southern Denmark
2 shared publicationsAnette Green Nielsen
Institute of Public Health, Clinical Pharmacology, University of Southern Denmark, Odense, Denmark
1 shared publicationCharlotte Brasch-Andersen
Institute of Public Health, Clinical Pharmacology, University of Southern Denmark, Odense, Denmark
1 shared publication
Latest Publications
- 2 March 2014
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 70 (4) , 507
Erratum to: A cytochrome P450 phenotyping cocktail causing unexpected adverse reactions in female volunteers
- 2 March 2014
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 70 (4) , 507
Erratum to: A cytochrome P450 phenotyping cocktail causing unexpected adverse reactions in female volunteers
- 6 August 2013
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 69 (12) , 1997-1999
A cytochrome P450 phenotyping cocktail causing unexpected adverse reactions in female volunteers
A four-drug cytochrome P450 (CYP) phenotyping cocktail was developed to rapidly and safely determine CYP2D6, CYP2C19, CYP2C9 and CYP1A2 enzyme activity and phenotype. The cocktail consisted of the single CYP phenotyping probes of 50 mg tramadol (CYP2D6), 20 mg omeprazole (CYP2C19), 25 mg losartan (CYP2C9) and 200 mg caffeine (CYP1A2) and was administered as a single oral dose. For enzyme activity measurements, urine was collected as 8 h post-administration and blood was sampled at 4 h. The enzyme activity was determined by metabolic ratios of molar concentrations of the drugs and their enzyme catalyzed metabolites and was correlated to the relevant genotypes. In a pilot study in 12 healthy male volunteers the CYP genotype–phenotype correlation and robustness of the cocktail was successfully determined without detection of any adverse drug reactions. In the subsequent population study, four female volunteers experienced unexpected and unacceptable moderate and severe adverse reactions (ARs) of headache, dizziness, nausea, vomiting, blue fingers, nails and lips and difficulties in urinating, which led to the study being prematurely terminated after inclusion of only 25 subjects (17 males, 7 females). Attention must be paid to adverse reactions when designing new combinations of phenotype cocktails regardless of the doses and drugs involved. We specifically warn against the combination of tramadol, omeprazole, losartan and caffeine.
- 6 August 2013
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 69 (12) , 1997-1999
A cytochrome P450 phenotyping cocktail causing unexpected adverse reactions in female volunteers
A four-drug cytochrome P450 (CYP) phenotyping cocktail was developed to rapidly and safely determine CYP2D6, CYP2C19, CYP2C9 and CYP1A2 enzyme activity and phenotype. The cocktail consisted of the single CYP phenotyping probes of 50 mg tramadol (CYP2D6), 20 mg omeprazole (CYP2C19), 25 mg losartan (CYP2C9) and 200 mg caffeine (CYP1A2) and was administered as a single oral dose. For enzyme activity measurements, urine was collected as 8 h post-administration and blood was sampled at 4 h. The enzyme activity was determined by metabolic ratios of molar concentrations of the drugs and their enzyme catalyzed metabolites and was correlated to the relevant genotypes. In a pilot study in 12 healthy male volunteers the CYP genotype–phenotype correlation and robustness of the cocktail was successfully determined without detection of any adverse drug reactions. In the subsequent population study, four female volunteers experienced unexpected and unacceptable moderate and severe adverse reactions (ARs) of headache, dizziness, nausea, vomiting, blue fingers, nails and lips and difficulties in urinating, which led to the study being prematurely terminated after inclusion of only 25 subjects (17 males, 7 females). Attention must be paid to adverse reactions when designing new combinations of phenotype cocktails regardless of the doses and drugs involved. We specifically warn against the combination of tramadol, omeprazole, losartan and caffeine.
- 11 July 2013
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 40 (10) , 683-688
Inhibitory effect of oral contraceptives on CYP2C19 activity is not significant in carriers of the CYP2C19*17 allele
Summary: The purpose of the present study was to examine whether cytochrome P450 2C19 (CYP2C19) in carriers of the CYP2C19*17 allele is inhibited in vivo by oral contraceptives (OC). Retrospective CYP2C19 phenotyping according to omeprazole : 5‐OH‐omeprazole molar 3 h plasma metabolic ratios (MR) from a population (n = 222) genotyped as CYP2C19*1/*1, CYP2C19*1/*17 and CYP2C19*17/*17 was analysed. Furthermore, 30 women genotyped as CYP2C19*1/*1 (n = 11), CYP2C19*1/*17 (n = 11) and CYP2C19*17/*17 (n = 8) were prospectively CYP2C19 phenotyped during the administration of OC and again after a minimum 5 days break from OC. We found a significantly higher MR in the CYP2C19*1/*1 genotype group that took OC (n = 48) compared with women who did not take OC (n = 31; geometric mean 1.37 vs 0.83, respectively; P < 0.05). However, in the CYP2C19*1/*17 genotype group, the geometric means of the MR in the 37 women taking OC and the 20 women not taking OC were 0.67 and 0.46, respectively (P > 0.05). In the CYP2C19*1/*1 panel of the prospective cross‐over study, we found a significantly higher MR while women were taking the OC compared with the MR during the OC break (geometric mean 1.21 vs 0.91, respectively; P = 0.0123). However, in the CYP2C19*1/*17 group, the geometric means of the MR with and without OC were 0.77 and 0.65, respectively, compared with 1.05 and 0.79, respectively, in the CYP2C19*17/*17 group (P = 0.20 and 0.17, respectively). In conclusion, we have shown that OC intake inhibits CYP2C19 in homozygous carriers of the CYP2C19 wild type but that the inhibition is not significant in heterozygous and homozygous carriers of the CYP2C19*17 allele.
- 11 July 2013
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 40 (10) , 683-688
Inhibitory effect of oral contraceptives on CYP2C19 activity is not significant in carriers of the CYP2C19*17 allele
Summary: The purpose of the present study was to examine whether cytochrome P450 2C19 (CYP2C19) in carriers of the CYP2C19*17 allele is inhibited in vivo by oral contraceptives (OC). Retrospective CYP2C19 phenotyping according to omeprazole : 5‐OH‐omeprazole molar 3 h plasma metabolic ratios (MR) from a population (n = 222) genotyped as CYP2C19*1/*1, CYP2C19*1/*17 and CYP2C19*17/*17 was analysed. Furthermore, 30 women genotyped as CYP2C19*1/*1 (n = 11), CYP2C19*1/*17 (n = 11) and CYP2C19*17/*17 (n = 8) were prospectively CYP2C19 phenotyped during the administration of OC and again after a minimum 5 days break from OC. We found a significantly higher MR in the CYP2C19*1/*1 genotype group that took OC (n = 48) compared with women who did not take OC (n = 31; geometric mean 1.37 vs 0.83, respectively; P < 0.05). However, in the CYP2C19*1/*17 genotype group, the geometric means of the MR in the 37 women taking OC and the 20 women not taking OC were 0.67 and 0.46, respectively (P > 0.05). In the CYP2C19*1/*1 panel of the prospective cross‐over study, we found a significantly higher MR while women were taking the OC compared with the MR during the OC break (geometric mean 1.21 vs 0.91, respectively; P = 0.0123). However, in the CYP2C19*1/*17 group, the geometric means of the MR with and without OC were 0.77 and 0.65, respectively, compared with 1.05 and 0.79, respectively, in the CYP2C19*17/*17 group (P = 0.20 and 0.17, respectively). In conclusion, we have shown that OC intake inhibits CYP2C19 in homozygous carriers of the CYP2C19 wild type but that the inhibition is not significant in heterozygous and homozygous carriers of the CYP2C19*17 allele.
- 4 April 2012
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 68 (10) , 1463-1464
Linkage disequilibrium between the CYP2C19*17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population
- 4 April 2012
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 68 (10) , 1463-1464
Linkage disequilibrium between the CYP2C19*17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population
- 28 July 2010
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 66 (12) , 1199-1205
Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations
Purpose To determine the distribution of clinically important CYP2C genotypes and allele frequencies in healthy Nordic populations with special focus on linkage disequilibrium. Methods A total of 896 healthy subjects from three Nordic populations (Danish, Faroese, and Norwegian) were genotyped for five frequent and clinically important CYP2C allelic variants: the defective CYP2C8*3, CYP2C9*2, CYP2C9*3, and CYP2C19*2 alleles, and the CYP2C19*17 allele that causes rapid drug metabolism. Linkage disequilibrium was evaluated and CYP2C haplotypes were inferred in the entire population. Results Ten CYP2C haplotypes were inferred, the most frequent of which (49%) was the CYP2C wildtype haplotype carrying CYP2C8*1, CYP2C9*1, and CYP2C19*1. The second most frequent haplotype (19%) is composed of CYP2C19*17, CYP2C8*1, and CYP2C9*1. This predicted haplotype accounts for 99.7% of the CYP2C19*17 alleles found in the 896 subjects. Conclusion CYP2C19*17 is a frequent genetic variant in Nordic populations that exists in strong linkage disequilibrium with wildtype CYP2C8*1 and CYP2C9*1 alleles, which effectively makes it a determinant for a haplotype exhibiting an efficient CYP2C substrate metabolism.
- 28 July 2010
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 66 (12) , 1199-1205
Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations
Purpose To determine the distribution of clinically important CYP2C genotypes and allele frequencies in healthy Nordic populations with special focus on linkage disequilibrium. Methods A total of 896 healthy subjects from three Nordic populations (Danish, Faroese, and Norwegian) were genotyped for five frequent and clinically important CYP2C allelic variants: the defective CYP2C8*3, CYP2C9*2, CYP2C9*3, and CYP2C19*2 alleles, and the CYP2C19*17 allele that causes rapid drug metabolism. Linkage disequilibrium was evaluated and CYP2C haplotypes were inferred in the entire population. Results Ten CYP2C haplotypes were inferred, the most frequent of which (49%) was the CYP2C wildtype haplotype carrying CYP2C8*1, CYP2C9*1, and CYP2C19*1. The second most frequent haplotype (19%) is composed of CYP2C19*17, CYP2C8*1, and CYP2C9*1. This predicted haplotype accounts for 99.7% of the CYP2C19*17 alleles found in the 896 subjects. Conclusion CYP2C19*17 is a frequent genetic variant in Nordic populations that exists in strong linkage disequilibrium with wildtype CYP2C8*1 and CYP2C9*1 alleles, which effectively makes it a determinant for a haplotype exhibiting an efficient CYP2C substrate metabolism.
- 31 March 2010
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 66 (7) , 655-660
Two separate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadol’s O-demethylation via CYP2D6
To investigate paroxetine’s putative dose-dependent impact on pupil reaction and inhibition of the O-demethylation of tramadol. Twelve healthy CYP2D6 extensive metabolizers participated in this double-blinded randomized five-way placebo controlled cross-over study; they received placebo, 10, 20, 30, and 50 mg paroxetine as single oral doses at bedtime. Next morning the pupil was measured followed by oral intake of 50 mg of tramadol, and urine was collected for 8 h. Three hours after ingestion of tramadol a second measurement of the pupil was performed. Enantioselective urine concentrations of (+/−)-tramadol and (+/−)-O-desmethyltramadol (M1) were determined. With placebo, the median maximum pupil diameter was 6.43 mm (range 5.45–7.75 mm) before tramadol and 6.22 mm (4.35–7.65 mm) after 50 mg of tramadol (P = 0.4935). Paroxetine resulted in a statistically significant, dose-dependent dilatation of the pupil with a geometric mean difference of 1.17 (95% CI 1.10–1.24) after ingestion of 50 mg paroxetine (P < 0.001). Likewise, a reduction in the relative constriction amplitude with a geometric mean difference of 0.81 (95% CI 0.71-0.92) (P < 0.001) was seen. A dose-dependent inhibition of the metabolism of tramadol by an increase in the two urinary metabolic ratios (+)-tramadol / (+)-M1 [geometric mean difference 9.09, 95% CI 5.60–14.73 (P < 0.001)] and (−)-M1 / (+)-M1 [geometric mean difference 2.84, 95% CI 2.15–3.77 (P < 0.001)] was also observed. Paroxetine is a dose-dependent dilator of the pupil and as expected a dose-dependent inhibitor of (+)-tramadol’s O-demethylation.
- 31 March 2010
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 66 (7) , 655-660
Two separate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadol’s O-demethylation via CYP2D6
To investigate paroxetine’s putative dose-dependent impact on pupil reaction and inhibition of the O-demethylation of tramadol. Twelve healthy CYP2D6 extensive metabolizers participated in this double-blinded randomized five-way placebo controlled cross-over study; they received placebo, 10, 20, 30, and 50 mg paroxetine as single oral doses at bedtime. Next morning the pupil was measured followed by oral intake of 50 mg of tramadol, and urine was collected for 8 h. Three hours after ingestion of tramadol a second measurement of the pupil was performed. Enantioselective urine concentrations of (+/−)-tramadol and (+/−)-O-desmethyltramadol (M1) were determined. With placebo, the median maximum pupil diameter was 6.43 mm (range 5.45–7.75 mm) before tramadol and 6.22 mm (4.35–7.65 mm) after 50 mg of tramadol (P = 0.4935). Paroxetine resulted in a statistically significant, dose-dependent dilatation of the pupil with a geometric mean difference of 1.17 (95% CI 1.10–1.24) after ingestion of 50 mg paroxetine (P < 0.001). Likewise, a reduction in the relative constriction amplitude with a geometric mean difference of 0.81 (95% CI 0.71-0.92) (P < 0.001) was seen. A dose-dependent inhibition of the metabolism of tramadol by an increase in the two urinary metabolic ratios (+)-tramadol / (+)-M1 [geometric mean difference 9.09, 95% CI 5.60–14.73 (P < 0.001)] and (−)-M1 / (+)-M1 [geometric mean difference 2.84, 95% CI 2.15–3.77 (P < 0.001)] was also observed. Paroxetine is a dose-dependent dilator of the pupil and as expected a dose-dependent inhibitor of (+)-tramadol’s O-demethylation.
- Open Access
- 12 July 2006
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 62 (6) , 682-689
The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects
Aims: To determine the effect ofCYP2C8genotype and of fluvoxamine on the pharmacokinetics of rosiglitazone.Methods: Twenty‐three healthy subjects with the following genotypes were included in a two‐phase, open‐label, cross‐over trial:CYP2C8*3/ *3(n = 3),CYP2C8*1/ *3(n = 10) andCYP2C8*1/ *1(n = 10). In Phase A, the subjects were given 4 mg rosiglitazone as a single oral dose. In Phase B, the subjects were treated with multiple oral doses of 50 mg fluvoxamine maleate for 3 days prior to the single oral administration of 4 mg rosiglitazone. Plasma concentrations of rosiglitazone and relative amounts ofN‐desmethylrosiglitazone were measured in both phases for 24 h after drug administration.Results: The pharmacokinetics of rosiglitazone andN‐desmethylrosiglitazone were not significantly different between theCYP2C8genotypic groups. Fluvoxamine caused a statistically significant (P = 0.0066) increase in the AUC0–∞of rosiglitazone, with a geometric mean ratio of 1.21 [95% confidence interval (CI) 1.06–1.39]. The elimination half‐life (t1/2) was also significantly higher (P = 0.0203) with a geometric mean ratio of 1.38 [95% CI 1.06–1.79]. The coadministration of fluvoxamine had no influence on the pharmacokinetics ofN‐desmethylrosiglitazone.Conclusion: The importance of theCYP2C8*3mutation in thein vivometabolism of rosiglitazone could not be confirmed. Fluvoxamine increased the AUC0–∞andt1/2of rosiglitazone moderately and hence may be a weak inhibitor of CYP2C8.
- 12 July 2006
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 62 (6) , 682-689
Open AccessThe effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects
Aims: To determine the effect ofCYP2C8genotype and of fluvoxamine on the pharmacokinetics of rosiglitazone.Methods: Twenty‐three healthy subjects with the following genotypes were included in a two‐phase, open‐label, cross‐over trial:CYP2C8*3/ *3(n = 3),CYP2C8*1/ *3(n = 10) andCYP2C8*1/ *1(n = 10). In Phase A, the subjects were given 4 mg rosiglitazone as a single oral dose. In Phase B, the subjects were treated with multiple oral doses of 50 mg fluvoxamine maleate for 3 days prior to the single oral administration of 4 mg rosiglitazone. Plasma concentrations of rosiglitazone and relative amounts ofN‐desmethylrosiglitazone were measured in both phases for 24 h after drug administration.Results: The pharmacokinetics of rosiglitazone andN‐desmethylrosiglitazone were not significantly different between theCYP2C8genotypic groups. Fluvoxamine caused a statistically significant (P = 0.0066) increase in the AUC0–∞of rosiglitazone, with a geometric mean ratio of 1.21 [95% confidence interval (CI) 1.06–1.39]. The elimination half‐life (t1/2) was also significantly higher (P = 0.0203) with a geometric mean ratio of 1.38 [95% CI 1.06–1.79]. The coadministration of fluvoxamine had no influence on the pharmacokinetics ofN‐desmethylrosiglitazone.Conclusion: The importance of theCYP2C8*3mutation in thein vivometabolism of rosiglitazone could not be confirmed. Fluvoxamine increased the AUC0–∞andt1/2of rosiglitazone moderately and hence may be a weak inhibitor of CYP2C8.
- 9 June 2006
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 62 (7) , 513-521
Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers
To describe in detail the intravenous, single oral and multiple oral dose enantioselective pharmacokinetics of tramadol in CYP2D6 extensive metabolizers (EMs) and poor metabolizers (PMs). Eight EMs and eight PMs conducted three phases as an open-label cross-over trial with different formulations; 150 mg single oral tramadol hydrochloride, 50 mg single oral tramadol hydrochloride every 8 h for 48 h (steady state), 100 mg intravenous tramadol hydrochloride. Urine and plasma concentrations of (+/−)-tramadol and (+/−)-M1 were determined for 48 h after administration. In all three phases, there were significant differences between EMs and PMs in AUC and t1/2 of (+)-tramadol (P≤0.0015), (−)-tramadol (P≤0.0062), (+)-M1 (P≤0.0198) and (−)-M1 (P≤0.0370), and significant differences in Cmax of (+)-M1 (PP≤0.0010). In Phase A and C, significant differences in tmax were seen for (+)-M1 (P≤0.0200). There were no statistical differences between the absolute bioavailability of tramadol in EMs and PMs. The urinary recoveries of (+)-tramadol, (−)-tramadol, (+)-M1 and (−)-M1 were statistically significantly different in EMs and PMs (PO-demethylation of tramadol was catalysed stereospecific by CYP2D6 in the way that very little (+)-M1 was produced in PMs.
- 9 June 2006
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 62 (7) , 513-521
Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers
To describe in detail the intravenous, single oral and multiple oral dose enantioselective pharmacokinetics of tramadol in CYP2D6 extensive metabolizers (EMs) and poor metabolizers (PMs). Eight EMs and eight PMs conducted three phases as an open-label cross-over trial with different formulations; 150 mg single oral tramadol hydrochloride, 50 mg single oral tramadol hydrochloride every 8 h for 48 h (steady state), 100 mg intravenous tramadol hydrochloride. Urine and plasma concentrations of (+/−)-tramadol and (+/−)-M1 were determined for 48 h after administration. In all three phases, there were significant differences between EMs and PMs in AUC and t1/2 of (+)-tramadol (P≤0.0015), (−)-tramadol (P≤0.0062), (+)-M1 (P≤0.0198) and (−)-M1 (P≤0.0370), and significant differences in Cmax of (+)-M1 (PP≤0.0010). In Phase A and C, significant differences in tmax were seen for (+)-M1 (P≤0.0200). There were no statistical differences between the absolute bioavailability of tramadol in EMs and PMs. The urinary recoveries of (+)-tramadol, (−)-tramadol, (+)-M1 and (−)-M1 were statistically significantly different in EMs and PMs (PO-demethylation of tramadol was catalysed stereospecific by CYP2D6 in the way that very little (+)-M1 was produced in PMs.
- 27 July 2005
- Published by Springer Nature in Chromatographia
- Vol. 62 (3-4) , 197-201
HPLC Method for Determination of Rosiglitazone in Plasma
- 27 July 2005
- Published by Springer Nature in Chromatographia
- Vol. 62 (3-4) , 197-201
HPLC Method for Determination of Rosiglitazone in Plasma
- 12 March 2004
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 94 (3) , 151-152
Cytochrome P4502C9 (CYP2C9) Genotypes in a Nordic Population in Denmark
- 12 March 2004
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 94 (3) , 151-152
Cytochrome P4502C9 (CYP2C9) Genotypes in a Nordic Population in Denmark